Finding that many different B-Raf mutations are allowed to occur in colorectal cancer (as well as the fact that APC mutation dominates) is consistent with findings that B-RafV600E inhibitors are generally not therapeutically useful in this tumour type [31–33]. This evidence concerns the gene APC and neoplasm.